Patient Square Capital’s Post

Save the date and learn more about TRxA's 2024 Request for Proposals!

Source. Plan. Invest. Execute. These sound like simple directions, but in the context of pre-seed therapeutics investment the route can be hard to navigate. In the next chapter of Evotec’s White Paper series, ‘From academic concept to commercial reality: How to accelerate translational drug discovery’ we take a look from an investor’s perspective at the way-markers for a successful translational roadmap. Read chapter 2, 'Source. Plan. Invest. Execute. Navigating the tough roadmap of pre-seed therapeutics investment' here - https://hubs.ly/Q02j-Bfx0 #researchneverstops

I'm pleased to announce the addition of Jeeshan Chowdhury, MD, Ph.D., Chief Executive Officer & Co-Founder, Journey Colab to the agenda for the 4th Annual Psychedelic Therapeutics Conference, taking place in Boston on May 23-24, 2024. He will be discussing the issue of fundraising for psychedelic drug programs. In the ever-evolving landscape of drug development, securing later-stage funding remains a critical bottleneck, especially in the burgeoning field of psychedelic medicine. One of the key challenges currently facing drug development companies is navigating the complex path from research to commercialization. This session aims to introduce a groundbreaking approach to address this challenge. This session will be of particular interest to drug developers grappling with commercialization challenges. This approach is uniquely positioned to not only advance the clinical science but also to build a strategy for commercialization, thereby addressing the most pressing issue in the psychedelic industry today. Learn more about this event by visiting https://lnkd.in/eM5iiPn. #psychedelics #psychedelicresearch #psychedelictherapy #boston

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: September 25 - 26, 2024 (Get the full list of 30 news pieces in today's TLDR Biotech newsletter: https://lnkd.in/gKxuKwXw) • Bristol Myers Squibb’s historic schizophrenia FDA approval • ARCH Venture Partners $3B 13th fund • Genentech touts positive Ph3 Gazyva lupus data • CSL Seqirus nabs another BARDA bird flu contract • Mirai Bio launches as Flagship Pioneering’s newest endeavour • Novo Nordisk & Evotec partner to develop off-the-shelf stem-cell derived cell therapies • Inventiva Pharma’s coffers are weeks from running dry • Biogen and Sage Therapeutics discontinue essential tremor partnership • FDA adcomm advises narrower PD-1 inhibitor approvals • Top NIH neuroscientist conducted alleged widespread Parkinson’s & Alzheimer's research misconduct #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Odyssey Therapeutics Appoints William Roush, Ph.D., as EVP and Head of Small Molecule Research Learn more & get our take 👇 https://lnkd.in/gaApD7Ut “As a renowned scientist, Dr. Roush developed innovative solutions to complex problems in organic and medicinal chemistry, and under his leadership, has led multiple drug discovery programs from ideation into clinical development.” — Gary D. Glick, Ph.D., Founder and CEO at Odyssey Therapeutics “By collaborating with others at Odyssey, I hope to accelerate the discovery and development of small molecule medicines to enhance the quality of life for patients.” — Dr. William Roush, Executive Vice President and Head of Small Molecule Research at Odyssey Therapeutics #Biotech #Therapeutics #SoHCNews

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gfw7pkVK Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gT9Z6KEQ Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews

Exciting update from the 7th Alcor Drug Discovery Platform event at the Princeton Crown Plaza in New Jersey! Currently, Chad Beyer , COO of Channavix Therapeutics, LLC and Kures, is taking the stage to share his profound expertise. Topic: Unveiling Novel Mechanisms of Action for Inhibiting Clinically-Validated Analgesic Targets Dr. Beyer, with an illustrious career spanning over 25 years in CNS medication discovery and development, brings unparalleled insights to the forefront. He has spearheaded preclinical and clinical teams, contributed to over 30 IND submissions, and successfully commercialized two blockbuster drugs. His scholarly contributions extend to authoring over 70 manuscripts, co-editing "Next Generation Antidepressants," and co-founding the esteemed "Technology Transfer & Entrepreneurship" journal. Join us as we delve into the frontier of pharmaceutical innovation with Dr. Beyer, exploring groundbreaking strategies for targeting clinically-validated analgesic pathways. This promises to be a captivating session, illuminating the path towards next-generation therapeutics. Don't miss out on this opportunity to gain invaluable insights from a leader in the field! #ADDP2024 #7thADDP #Alcordrugdiscoveryplatform #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

The covalency renaissance is heating up, as funding and collaboration fuel the development of chemoproteomic platforms and innovative modalities for hard-to-drug targets. December's 2nd Covalent Drug Discovery & Development Summit will reunite 100+ covalency specialists to deep dive into topics like: 🔹 Overcoming challenges in balancing reactivity and sensitivity with advanced screening cascades with Genentech, Scorpion Therapeutics, Amgen and Covant Therapeutics 🔹 Unlocking novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome with Hyku Biosciences, Bayer and Nexo Therapeutics 🔹 Exploring the advancing paradigm of covalent PROTACs and monovalents with the latest developments from Vividion Therapeutics, Inc., Baylor College of Medicine, Pfizer and Harvard University Download your copy of the program here: https://ter.li/76az03 #covalent #covalency #drugdiscovery #smallmolecule

Join us as our CEO, Hugues Wallemacq, takes the stage to present EXO Biologics' latest advancements at the Exosome-Based Therapeutic Development Summit in Boston! 🗓️ Date: Wednesday, September 18, 2024 🕒 Time: 9:30 - 10:00 AM 📍 Location: Plenary Session Room, Hilton Airport Hotel 🎙️ Presenter: Hugues Wallemacq, CEO of EXO Biologics and ExoXpert He'll discuss "From ongoing Phase I/II trial to RNAs delivery preclinical demonstration," showcasing how we are pushing the boundaries of exosome-based therapeutics. For more information about the summit, visit: https://lnkd.in/gBdKPAgE While you're there, make sure to connect with Romain du Hecquet de Rauville, our Chief Business Officer, and Beatrice De Vos, our Chief Medical Officer, to explore partnership opportunities and share insights into the exosome landscape. We can't wait to see you there! #Exosomes #Biotech #TherapeuticDevelopment #Innovation